Northwest Biotherapeutics, Inc.
NWBO
$0.2074
-$0.0026-1.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.42% | 2.42% | 3.21% | 19.57% | -62.80% |
| Total Depreciation and Amortization | 1.16% | 2.18% | 19.95% | -13.91% | 16.15% |
| Total Amortization of Deferred Charges | 12.22% | -14.76% | 57.38% | -49.86% | 0.83% |
| Total Other Non-Cash Items | 3,829.17% | -110.87% | -75.04% | -24.88% | 1,415.44% |
| Change in Net Operating Assets | 356.54% | -74.60% | 165.33% | -3,685.00% | -88.69% |
| Cash from Operations | 49.17% | -30.56% | 26.84% | -21.83% | -20.81% |
| Capital Expenditure | 66.22% | -117.99% | 42.82% | 4.35% | 65.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 66.22% | -117.99% | 42.82% | 4.35% | 65.01% |
| Total Debt Issued | -51.85% | 40.85% | -33.31% | -7.82% | 905.22% |
| Total Debt Repaid | -222.09% | -- | -- | -8,650.00% | 98.13% |
| Issuance of Common Stock | 132.04% | 134.71% | 1,001.68% | 271.88% | -97.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -93.81% | 18.93% | 5.63% | -33.29% | 116.91% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -87.28% | -1.75% | -89.76% |
| Cash from Financing | -32.20% | 41.81% | -16.16% | -15.81% | 98.23% |
| Foreign Exchange rate Adjustments | -18,447.06% | -101.86% | 190.30% | -152.99% | 400.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -85.61% | 14.49% | 108.86% | -184.98% | 198.03% |
